A carregar...
Economic Evaluation of Rituximab + Recombinant Human Thrombopoietin vs. Rituximab for the Treatment of Second-Line Idiopathic Thrombocytopenic Purpura in China
Objective: This study aimed to compare the economic evaluation of recombinant human thrombopoietin+rituximab (rhTPO + RTX) vs. RTX as second-line treatment for adult patients with immunologic thrombocytopenic purpura in China. Methods: The Markov model was used in our research. The response rate and...
Na minha lista:
| Publicado no: | Front Med (Lausanne) |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8012846/ https://ncbi.nlm.nih.gov/pubmed/33816534 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2021.657539 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|